医学
卡培他滨
奥沙利铂
不利影响
耐受性
内科学
氟尿嘧啶
胃肠病学
结直肠癌
恶心
养生
丸(消化)
人口
辅助治疗
外科
癌症
环境卫生
作者
Hans‐Joachim Schmoll,Thomas H. Cartwright,Josep Tabernero,Marek P. Nowacki,Arié Figer,Jean A. Maroun,Timothy Price,Robert Lim,Eric Van Cutsem,Young Suk Park,Joseph McKendrick,Claire Topham,Gemma Soler,Filippo de Braud,Mark Hill,Florin Sirzén,Daniel G. Haller
标识
DOI:10.1200/jco.2006.08.1075
摘要
Purpose To report the results of a planned safety analysis from a phase III trial comparing capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil/leucovorin (FU/LV) as adjuvant therapy for stage III colon cancer. Patients and Methods Patients with stage III colon carcinoma were randomly assigned to receive either XELOX (intravenous oxaliplatin plus oral capecitabine; 3-week cycle for eight cycles) or standard intravenous bolus FU/LV administered as the Mayo Clinic (Mayo; Rochester, MN) or Roswell Park (RP; Buffalo, NY) regimen for a similar length of time. A total of 1,886 patients were randomly assigned. Results The safety population comprised 1,864 patients, of whom 938 received XELOX and 926 received FU/LV. Most treatment-related adverse events (AEs) occurred at similar rates in both treatment arms. However, patients receiving XELOX experienced less all-grade diarrhea, alopecia, and more neurosensory toxicity, vomiting, and hand-foot syndrome than those patients receiving FU/LV. Compared with Mayo, XELOX showed fewer grade 3/4 hematologic AE and more grade 3/4 gastrointestinal AE. Compared with RP, XELOX showed less grade 3/4 gastrointestinal AE and more grade 3/4 hematologic AE. As expected grade 3/4 neurosensory toxicity and grade 3 hand-foot syndrome were higher with XELOX. Treatment-related mortality within 28 days from the last study dose was 0.6% in the XELOX group and 0.6% in the FU/LV group. Conclusion XELOX has a manageable tolerability profile in the adjuvant setting. Efficacy data will be available within the next 24 months.
科研通智能强力驱动
Strongly Powered by AbleSci AI